Stockreport

UroGen Pharma Announces Podium Presentation of Final Jelmyto® Data From Pivotal OLYMPUS Trial at the Annual Meeting of the Society of Urologic Oncology

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF Clinically Meaningful Response Underscores Potential for Jelmyto to Become New Standard of Care for Patients with Low-Grade Upper Tract Urothelial CancerOf the 58% of Pa [Read more]